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SUMMARY The last decades have witnessed an increasing interest in 
psychological aspects of chronic skin disease. Psoriasis has received 
much attention, partly due to the pivotal change brought to therapeutic 
concepts by biologics. This article aims to provide a brief overview, with 
no claims on exhaustiveness, on recent (i.e. stemming from the last 10-
15 years) publications on psychodermatological research in psoriasis, 
with particular reference to those results that have shown in the past or 
may show in the near future important consequences for clinical prac-
tice (i.e. patient education models, psychotropic effects of TNF-alpha 
antagonists and others). Some considerations are presented on the dif-
ficulties encountered on performing clinical studies of non pharmaco-
logical interventions. The possible beneficial effect of e-Health projects 
is discussed.
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IntRODUCtIOn
 Both the interest in psychodermatology and, 
consequently, the number of related publications 
have been rapidly and steadily growing in the 
last decades. A simple Medline search performed 
in 2009 with the terms “psychological” and “skin” 
showed 546 articles published until 1975, 875 ar-
ticles between 1976 and 1991, and 1827 articles 
published afterwards, suggesting that the number 
of publications  on psychodermatology may roughly 
be doubling every 15-16 years. This increase of in-
terest is paralleled by an increase in publications on 
psychological aspects of psoriasis: analogously, a 
Medline search performed with the keywords “pso-
riasis” and “psychological” yielded a total of 395 
articles, 34 of these published before 1980, 39 be-
tween 1980 and 1899, 95 between 1990 and 1999, 
and the remaining 228 (!) in the new millennium.  
 If one strives to summarize in a few sentences 
the state-of-the-art on “Psoriasis and Psyche” at 
the end of the 1990s, one can reasonably state 
that,  by the end of the century,
a)  psoriasis had been recognized, on the basis 
of research made mostly with the support of 
validated questionnaires, to be associated 
with high psychiatric morbidity, in particular 
with anxiety, depression, social withdrawal, 
significant reduction of the quality of life (QoL), 
and feelings of stigmatization (1) (whereby the 
nature of the correlation between the exten-
sion of affected skin, or, more generally, the 
disease severity and the severity of the psy-
chosocial impairments still warrants further 
investigation); and
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b)  the interaction between lifestyle factors (stress, 
body mass index, food, alcohol consumption, 
smoking habits, etc.) and psoriasis had been 
widely accepted and ever more supported by 
epidemiological data (2).
 Nevertheless, a closer look on the present 
knowledge on the interaction between psoriasis 
and psyche shows that this knowledge parallels 
the general situation in psychodermatology: a wide 
range of theoretical knowledge has been harvest-
ed but only little clinical, evidence based research 
is available for the immediate benefit of patients. 
This article aims to present a short overview of 
recent research on psoriasis and psyche, with no 
claims on exhaustiveness and, on the other hand, 
with a focus on those results, both theoretical and 
clinical, that may soon entail implications for the 
daily practice. 
WhAt’S nEW AnD ClInICAllY 
SIgnIfICAnt In bASIC RESEARCh 
On pSORIASIS AnD pSYChE?
a) It is well known that psychological stress al-
ters cutaneous barrier homeostasis. Recently, 
more publications have provided ever more 
and sounder evidence to this fact. This ex-
plains partly the influence of stress on pso-
riasis (and atopic dermatitis) since antigens 
and other immune triggering factors may be 
facilitated by stress in penetrating the skin and 
inducing relapses of the skin condition. This 
mechanism is presumably glucocorticoid me-
diated (3,4).
b) An interesting result on how stress may act 
on the immune system in psoriasis has been 
published (5). As a matter of fact, psoriasis 
patients seem to develop a stronger increase 
of CLA+ CD3+ cells (compared to controls) 
after stress. (A similar result was obtained for 
atopic eczema patients). As observed by the 
Schmid-Ott et al., this may point to the fact 
that stress induces an increase in a circulat-
ing NK lymphocyte subpopulation which has 
the ability to adhere and emigrate into the 
skin. Whether this has anything to do to a 
disease specific interaction between NK cells 
and dermal dendritic cells in lesional skin, as 
it has been claimed to be the case for atopic 
eczema, remains an open issue for psoriasis, 
worthy of further investigations.
c) That the relationship between stress and 
psoriasis may be more complicated than a 
sheer causative one has been suggested by 
an interesting observational study (6) in nine 
psoriatic patients over an observation period 
of 210 days at the most, whereby control of 
blood stress parameters, VAT stress assess-
ment and recording of worsening of the dis-
ease where regularly performed. In this small 
group, no correlation between the increase in 
stress level and worsening of psoriasis sta-
tus (assessed by PASI) could be established. 
With all limitations due to the very limited 
number of patients observed, this study is 
worth of praise for being the very first obser-
vational study in the field and for suggesting 
that the stress-psoriasis interaction warrants 
further investigation and more sophisticated 
models. (Since relaxation techniques seem to 
improve response to therapy (7), stress could, 
for instance, act on psoriasis by lowering the 
threshold of effectiveness of other cofactors 
(e.g., endogenous factors) in the aetiology of 
worsening episodes).
d) Some research suggests that inflammatory 
states may be directly linked with states of de-
pression, since some inflammatory cytokines 
seem to be implicated in depression (VIP, sub-
stance P, tumor necrosis factor alpha (TNF-a)). 
Conversely, there are reasons to believe that 
anti-TNF-a therapy in psoriasis may decrease 
the levels of depression, independently of the 
direct effect on the skin condition (8-11).
WhAt IS nEW AnD ClInICAllY 
SIgnIfICAnt In pSYChOMEtRIC 
ASSESSMEnt Of DERMAtOlOgIC 
pAtIEntS?
 Psychometric techniques have increasingly 
been applied in chronic dermatologic disease in 
order to show:
a) the prevalence of certain psychopathological 
conditions in selected patient groups; and 
b) the benefits of therapies that go beyond pure 
clinical improvement.
 Assessments of psychopathological conditions 
such as depression or alexithymia are generally 
performed cross-sectionally (i.e. aiming to show 
that, for instance, depression or alexithymia is 
over-represented in psoriatic patients)
 Clinical studies, on the other hand, are mostly 
associated with longitudinal QoL assessments, i.e. 
research aims to show that certain pharmaceuti-
cal therapies are linked not only with clinical (such 
as PASI reduction) but also with significant QoL 
improvement.
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 From the point of view of searching a more im-
mediate benefit for the patient, longitudinal studies 
assessing improvement of psychometric values 
under a certain therapy are, of course, more inter-
esting. 
 Three important concepts have recently been 
introduced in psychometrics that may have impor-
tant practical consequences:
a)  the concept of suffering and the measurement 
of the burden or impact of a chronic disease 
through a visual test, developed about 10 
years ago. The measure, Pictorial Represen-
tation of Illness and Self Measure (PRISM), 
takes less than 5 minutes to complete and 
is unusual in relying only minimally on lan-
guage. PRISM has first been developed as 
a research tool and has subsequently been 
used effectively in routine clinical practice. In 
the basic PRISM test, patients are shown, by 
the treating physician, a white A4-size metal 
board with a fixed, yellow circle 7 cm in di-
ameter in the bottom right-hand corner. The 
patient is asked to imagine that the board 
represents his/her life as it is currently, and 
the yellow disk represents the patient’s “self.” 
The patient is then handed a red disk, 5 cm in 
diameter, with a magnetic strip on its under-
side, so that it can be attached to the board. 
The patient is asked to imagine that the red 
disk represents his/her illness and is asked, 
“where would you put the illness disk in your 
life at the moment?” The main outcome of the 
test is the distance between the centers of the 
yellow and the red disk, defined by the authors 
as SIS (self-illness separation) and appears to 
be inversely proportional to the burden of the 
disease. Used by the treating physician, the 
test appears to be a useful tool to get quickly 
“in medias res” as concerns the impact the 
disease has on the patient’s well being. Also, 
SIS appears not to correlate with the disease 
activity or the functional impairment caused 
by the illness, and it is reasonable to believe 
that it does provide a measure of discomfort 
that lies in “new, different” dimension of the 
patient’s existence. A few studies on the use 
of PRISM in psoriasis patients have already 
been published (12-14);  It would be worth 
exploring whether physicians regularly using 
PRISM in their clinical daily practice achieve, 
on the average, a better communication with 
their patients.
b) a new test has been developed and validat-
ed by a German group, the Skin Satisfaction 
Questionnaire (SSQ), which aims to assess 
satisfaction and attitudes towards one’s skin. 
As the authors put it, “the SSQ expands the 
existing spectrum of dermatological-psycho-
somatic/psychological questionnaires, which 
primarily address issues like coping with 
disease, quality of life, stigmatization and 
disease-specific problems, and includes un-
derlying deep-psychological aspects such as 
the role of the skin in regulating closeness 
and distance”. Although not yet widely imple-
mented in practice, this tool might be useful 
in showing the efficacy of psychotherapeu-
tic interventions in psoriasis patients, when-
ever such interventions may aim to improve 
the sense of well being of the patients 
and their coping with the chronic disease 
(15);
c) the increasing awareness that a chronic dis-
ease has a deep impact not only on the pa-
tient him/herself, but also on the patient’s fam-
ily and social ambiance has lead Finlay and 
Basra to introduce the concept of The Greater 
Patient. The term is inspired by an analogy 
with a descriptor applied to some of the world’s 
major cities, such as “Greater London”, and it 
is meant to describe “the patient himself along 
with the immediate close social group that 
is invariably affected by the changes in the 
patient’s life caused by the disease”. This 
concept underscores the paramount impor-
tance of taking social and family factors into 
account whenever a strategy is chosen for 
the treatment of a chronic disease: chron-
ic skin diseases do not only affect the pa-
tient’s QoL, but also the QoL of the family 
and of the closer social circle (16). A corre-
sponding questionnaire, The Psoriasis Fam-
ily Index, has subsequently been developed 
(17).
 Finally, there is the need for more research on 
the long-debated relationship between psoriasis 
and alexithymia, where results are not unequivo-
cal yet (18). Alexithymia is a term coined as late 
as 1973 to describe the state of deficiency in be-
ing aware of, understanding, processing, or de-
scribing emotions. While it still remains an open 
issue whether alexithymia is over-represented in 
psoriatic patients as compared with healthy con-
trols, an interesting report shows that low levels 
of emotional awareness predict better response to 
dermatologic treatment in patients with psoriasis 
(19).
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WhAt IS nEW AnD ClInICAllY  
SIgnIfICAnt In pSYChOphARMACO-
lOgIC IntERvEntIOnS In pSORIAtIC 
pAtIEntS?
 Although case reports have suggested the pos-
sible efficacy of antidepressant therapy in psoria-
sis, no significant news seem to have appeared 
on the subject since the publication of a small, but 
nevertheless significant study on the efficacy of 
bupropion in psoriasis and atopic dermatitis (20). 
It has been suggested that bupropion may have 
acted through lowering the levels of the proinflam-
matory cytokine TNF-a (21). On the other hand, 
the same drug has been associated with gener-
alized pustular and erythrodermic psoriasis (22). 
Hence, the interplay of proinflammatory cytokines, 
mood disorders, inflammatory skin disease and 
the possible role of psychopharmacological drugs 
in psoriasis remains an issue that warrants further 
research (8).
WhAt IS nEW AnD ClInICAllY 
SIgnIfICAnt In pSYChOlOgICAl 
IntERvEntIOnS In pSORIAtIC 
pAtIEntS?
 The importance of lifestyle factors in the man-
agement of both psoriasis and atopic dermatitis is 
being increasing recognized. However, while the 
effect of educational interventions in atopic der-
matitis has already been the object of multicenter, 
randomized studies (23) and of as much as a Co-
chrane review (24), education of psoriasis patients 
is still almost a virgin land. The Task Force on Der-
matological Prevention of the German Dermato-
logical Society has issued guidelines (25) on how 
to structure educational programs, but so far only 
pilot studies have been published on this issue 
(26).
 Going beyond the educational interventions, 
studies concerning the efficacy of other psycho-
logical interventions such as meditation, relax-
ation techniques, cognitive behavioural therapy 
and many others are generally encouraging but, 
although mostly controlled, limited to small num-
bers of patients and run over very short periods of 
time (27). This should not discourage dermatolo-
gists to address this issue whenever possible. A 
review on the indication of psychological interven-
tion in psoriasis patients has recently been pub-
lished, and the authors stress the need of rational 
criteria to select patients that might benefit most 
from such interventions (28).
 A promising and interesting strategy is the one 
of “written emotional disclosure” (29), developed 
by the USA psychologist J. Pennabaker. This 
technique, consisting of encouraging patients to 
write, under certain controlled conditions, about 
traumatic events they experienced during their 
life, has been shown to act with modulating effects 
on the immune system and has produced interest-
ing results in, among others, asthma and rheuma-
toid arthritis patients (30) as well as in the field 
of wound healing (31). The first published study 
(32) on psoriasis patients has not brought an un-
equivocal picture of the efficacy, but more exten-
sive and differently designed studies may provide 
promising results.
 Finally, a Dutch group has been investigating 
the clinical and psychological benefit of system-
atic QoL assessment in clinical practice. Such 
assessment can be practiced with the help of e-
Health techniques (computer assisted interviews, 
etc.) (33). This is likely to be a promising field of 
research and the patient-physician relationship, 
hence the patients themselves will probably take 
advantage of systematic inclusion of questions 
concerning their quality of life during dermatologic 
consultations. Physicians will be more inclined to 
address issues that are relevant to the patients 
and to verify whether the therapies chosen will 
be conducive to better patient satisfaction; hence, 
benefits of such systematic interventions might be 
conducive to:
1)  improvement of awareness and empower-
ment of the patient;
2) improvement of patient centeredness of the 
dermatologist;
3) provider of relevant, additional information for 
dermatologic treatment; 
4) improvement of compliance; and
5) improvement QoL and patient satisfaction (De 
Korte J., personal communication, 2009).
thE fUtURE
 The issue of how to cover the costs not only of 
all such interventions but also of the clinical studies 
that are supposed to assess their efficacy remains 
unsolved. Clinical research in psychodermatology 
is generally independent, and the problem of how 
to fund such research is far from being solved.
 Trying to shift psychological interventions when-
ever possible from the field of conventional, face 
to face medicine to the methods of e-Health (like 
for instance, but not only, Internet based patient 
education programs) may be a method that could 
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prove conducive to interesting results. Like many 
other problems presenting in this era of increased 
global financial difficulties, the solution could lie 
ahead, in using more and better technology, rath-
er than in going back to the methods of the past. 
As the title of a film that is already more than 25 
years old suggests, we may have to go back to 
the future.
References
1.   Griffiths CE, Richards HL. Psychological in-
fluences in psoriasis. Clin Exp Dermatol 
2001;26:338-42
2.   Naldi L, Chatenoud L, Linder D, Belloni Forti-
na A, Peserico A, Virgili AR et al. Cigarette 
smoking, body mass index, and stressful life 
events as risk factors for psoriasis: results 
from an Italian case-control study. J Invest 
Dermatol 2005;125:61-7
3.   Choi EH, Brown BE, Crumrine D, Chang S, 
Man MQ, Elias PM, et al. Mechanisms by which 
psychologic stress alters cutaneous permeabi-
lity barrier homeostasis and stratum corneum 
integrity. J Invest Dermatol 2005;124:587-95
4.   Choi EH, Demerjian M, Crumrine D, Brown 
BE, Mauro T, Elias PM, et al. Glucocorticoid 
blockade reverses psychological stress-indu-
ced abnormalities in epidermal structure and 
function. Am J Physiol Regul Integr Comp 
Physiol 2006;291:R1657-62
5.   Schmid-Ott G, Jaeger B, Boehm T, Langer 
K, Stephan M, Raap U, et al. Immunological 
effects of stress in psoriasis. Br J Dermatol 
2009;160:782-5
6.   Buentke E, Heffler LC, Wilson JL, Wallin RP, 
Löfman C, Chambers BJ, et al. Natural killer 
and dendritic cell contact in lesional atopic 
dermatitis skin – Malassezia-influenced cell 
interaction. J Invest Dermatol 2002;119:850-7
7.   Kabat-Zinn J, Wheeler E, Light T, Skillings 
A, Scharf M, Cropley TG, et al. Influence of 
a mindfulness-based stress reduction inter-
vention on rates of skin clearing in patients 
with moderate to severe psoriasis undergoing 
phototherapy (UVB) and photochemotherapy 
(PUVA). Psychosom Med 1998;60:625-32
8.   Maes M. The cytokine hypothesis of depres-
sion: inflammation, oxidative and nitrosative 
stress (IO&NS) and leaky gut as new targets 
for adjunctive treatments in depression. Neu-
roendocrinol Lett 2008;29:287-91
9.    Miller AH, Maletic V, Raison CL. Inflammation 
and its discontents: the role of cytokines in the 
pathophysiology of  major depression. Biol 
Psychiatry 2009; 65(9): 732–41.
10. Tyring S, Gottlieb A, Papp K, Gordon K, Leo-
nardi C, Wang A, et al. Etanercept and clinical 
outcomes, fatigue, and depression in psoria-
sis: double-blind placebo-controlled randomi-
sed phase III trial. Lancet 2006;367:29-35
11. Bos JD, de Korte J. Effects of etanercept on 
quality of life, fatigue, and depression in pso-
riasis. Lancet 2006;367:6-7
12. Büchi S, Sensky T. PRISM: Pictorial Repre-
sentation of Illness and Self Measure. A brief 
nonverbal measure of illness impact and th-
erapeutic aid in psychosomatic medicine. Psy-
chosomatics 1999;40:314-20
13. Reimus JL, Vingerhoets AJ, Soons PH, et al. 
Suffering in psoriasis patients: its relation with 
illness severity and subjective well-being. Int J 
Dermatol 2007 Oct;46(10):1042-5.
14. Muhleisen B, Buchi S, Schmidhauser S, Je-
newein J, Feuch LE, Hofbauer GF. Pictorial 
Representation of Illness and Self Measure 
(PRISM): a novel visual instrument to mea-
sure quality of life in dermatological inpatients. 
Arch Dermatol. 2009;145(7):774-780.
15. Grolle M, Kupfer J, Brosig B, Korstanje MJ. 
The Skin Satisfaction Questionnaire – an in-
strument to assess attitudes toward the skin in 
healthy persons and patients. Dermatol Psy-
chosom 2003;4:14-20.
16. Basra MKA, Finlay AY. The family impact of 
skin diseases: the Greater Patient concept. Br 
J Dermatol 2007;156:929-37.
17. Eghlileb AM, Basra MK, Finlay AY. The Pso-
riasis Family Index: preliminary results of vali-
dation of a quality of life instrument for family 
members of patients with psoriasis. Dermato-
logy 2009 Mar 13. [Epub ahead of print]
18. Richards HL, Fortune DG, Griffiths CE, Main 
CJ. Alexithymia in patients with psoriasis: clini-
cal correlates and psychometric properties of 
the Toronto Alexithymia Scale-20. J Psycho-
som Res 2005;58:89-96
19. Consoli SM, Rolhion S, Martin C, Ruel K, 
Cambazard F, Pellet J, et al. Low levels of 
emotional awareness predict a better re-
sponse to dermatological treatment in patients 
with psoriasis. Dermatology 2006;212:128-
36.
20. Modell JG, Boyce S, Taylor E, Katholi C. Tre-
atment of atopic dermatitis and psoriasis vul-
Linder and Forchetti       Acta Dermatovenerol Croat
Psoriasis and psyche       2009;17(3):198-203
203ACTA DERMATOVENEROLOGICA CROATICA
garis with bupropion-SR: a pilot  study. Psy-
chosom Med 2002;64:835-40.
21. Altschuler EL, Kast RE. Bupropion in pso-
riasis and atopic dermatitis: decreased tu-
mor necrosis factor-alpha? Psychosom Med 
2003;65:719.
22. Cox NH, Gordon PM, Dodd H. Generalized 
pustular and erythrodermic psoriasis associa-
ted with bupropion treatment. Br J Dermatol 
2002;146:1061-3.
23. Staab D, Diepgen TL, Fartasch M, Kupfer 
J, Lob-Corzilius T, Ring J, et al. Age related, 
structured educational programmes for the 
management of atopic dermatitis in children 
and adolescents: multicentre, randomised 
controlled trial. BMJ 2006;332:933-8.
24. Ersser SJ, Latter S, Sibley A, Satherley PA, 
Welbourne S. Psychological and educational 
interventions for atopic eczema in children. 
Cochrane Database Syst Rev 2007 Jul 18;(3):
CD004054.
25. Werfel T, Breitbart E, Kleinheinz A, Geiler U, 
Schmidt-Ott G. Psoriasisschulung für Patien-
ten nach den Regeln der Arbeitsgemeinschaft 
Dermatologische Praevention: Aktueller Stand 
(The educational program for the management 
of psoriasis vulgaris according to the rules of 
the Task Force on Dermatological Prevention: 
current status). Hautarzt 2006;57:913-6
26. Bonnekoh B, Schmid-Ott G, Herold S, Saye-
gh-Jodehl S, Dierkes J, Gollnick H. Interdis-
ziplinäre Psoriasisschulung in Blockform. 
Ein Halbjahres-Follow-Up. (Interdisciplinary 
training program for adults with psoriasis: six 
month follow-up). Hautarzt 2006;57:917-22
27. Levenson JL. Psychiatric issues in dermato-
logy. Part 1: Atopic dermatitis and psoriasis. 
Primary Psychiatry 2008;15:35-8
28. Janowski K, Pietrzak A. Indications for psy-
chological intervention in patients with psoria-
sis. Derm Ther 2008;21:409-11.
Linder and Forchetti       Acta Dermatovenerol Croat
Psoriasis and psyche       2009;17(3):198-203
I do not have painful feet any more! Saltrat Rodell cream; year 1934.
(From the collection of Mr. Zlatko Puntijar)
